Patient-derived xenografts for individualized care in advanced sarcoma.
Patient-derived xenografts for individualized care in advanced sarcoma.
复制标题
DOI：
10.1002/cncr.28696
复制
发表时间：
2014-07-01
期刊：
影响因子：
6.2
通讯作者：
Sidransky, David
中科院分区：
文献类型：
--
作者：
Stebbing, Justin;Paz, Keren;Schwartz, Gary K.;Wexler, Leonard H.;Maki, Robert;Pollock, Raphael E.;Morris, Ronnie;Cohen, Richard;Shankar, Arjun;Blackman, Glen;Harding, Victoria;Vasquez, David;Krell, Jonathan;Ciznadija, Daniel;Katz, Amanda;Sidransky, David
晚期转移性肉瘤患者预后差，并且可用的少数标准治疗的总体获益很小。这种肿瘤的罕见性，加上广泛的亚型，导致难以进行临床试验。作者先前报告了接受药物方案治疗的各种常见实体瘤患者的结局，这些药物方案首先使用专有方法（“TumorGrafts”）在患者来源的异种移植物中进行测试。将29例肉瘤患者切除的肿瘤植入免疫缺陷小鼠体内，以确定药物靶点和临床使用的药物。TumorGrafts的药物敏感性测试结果用于个性化癌症治疗。在29个植入的肿瘤中，22个（76%）成功植入，允许确定这些患者的治疗方案。尽管6名患者在完成TumorGraft测试前死亡，但在其余16名患者中的13名（81%）中观察到TumorGraft结果与临床结局之间的相关性。在TumorGraft预测治疗期间，无患者发生进展。目前的数据支持使用个性化TumorGraft模型作为治疗决策的研究平台，可以指导罕见肿瘤（如肉瘤）的治疗。一个随机的3期试验与医生的选择是必要的。
Patients with advanced, metastatic sarcoma have a poor prognosis, and the overall benefit from the few standard-of-care therapeutics available is small. The rarity of this tumor, combined with the wide range of subtypes, leads to difficulties in conducting clinical trials. The authors previously reported the outcome of patients with a variety of common solid tumors who received treatment with drug regimens that were first tested in patient-derived xenografts using a proprietary method (“TumorGrafts”). Tumors resected from 29 patients with sarcoma were implanted into immunodeficient mice to identify drug targets and drugs for clinical use. The results of drug sensitivity testing in the TumorGrafts were used to personalize cancer treatment. Of 29 implanted tumors, 22 (76%) successfully engrafted, permitting the identification of treatment regimens for these patients. Although 6 patients died before the completion of TumorGraft testing, a correlation between TumorGraft results and clinical outcome was observed in 13 of 16 (81%) of the remaining individuals. No patients progressed during the TumorGraft-predicted therapy. The current data support the use of the personalized TumorGraft model as an investigational platform for therapeutic decision-making that can guide treatment for rare tumors such as sarcomas. A randomized phase 3 trial versus physician's choice is warranted.
登录
查看更多内容
影响因子：
5.7
作者：
Villarroel MC;Rajeshkumar NV;Garrido-Laguna I;De Jesus-Acosta A;Jones S;Maitra A;Hruban RH;Eshleman JR;Klein A;Laheru D;Donehower R;Hidalgo M
通讯作者：
Hidalgo M
影响因子：
5.7
作者：
Hidalgo M;Bruckheimer E;Rajeshkumar NV;Garrido-Laguna I;De Oliveira E;Rubio-Viqueira B;Strawn S;Wick MJ;Martell J;Sidransky D
通讯作者：
Sidransky D
影响因子：
11.2
作者：
Baird, K;Davis, S;Meltzer, PS
通讯作者：
Meltzer, PS
影响因子：
45.3
作者：
Van Cutsem, Eric;Kohne, Claus-Henning;Ciardiello, Fortunato
通讯作者：
Ciardiello, Fortunato
影响因子：
50.3
作者：
Neve, Richard M.;Chin, Koei;Gray, Joe W.
通讯作者：
Gray, Joe W.